pharma · Hereditary Angioedema · Influenza · BCRX
Biocryst
NovaPharmaNews editorial coverage mentioning Biocryst — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- München, DE
- Founded
- 1986
- Employees
- 6
- Programs
- 37
- Drugs
- 17
- Patents
- 72
News & analysis
NovaPharmaNews articles mentioning Biocryst — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Biocryst — regulatory, clinical, and market analysis.
BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence
BioCryst Pharmaceuticals is presenting new clinical data and real-world evidence for ORLADEYO (berotralstat) in hereditary angioedema. The update matters because it expands the evidence base around an FDA-approved oral prophylactic option for adults and pediatric patients 2 years and older.
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
BioCryst Pharmaceuticals has secured a significant European deal for its rare disease drug, Navenibart, bolstering its portfolio and reaffirming its 2026 financial outlook. This strategic move positions the company for expanded market presence and potential revenue growth.
BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026
BioCryst Pharmaceuticals will present new hereditary angioedema (HAE) data for its oral therapy ORLADEYO® (berotralstat) and its investigational therapy navenibart at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. This presentation highlights BioCryst's ongoing commitment to advancing HAE treatment and understanding.